Company: Ariad Pharmaceuticals ( ARIA)

Drug/indication: Ridaforolimus for sarcoma

Estimated timing: Before year's end.

Recent stock performance: Closed Tuesday at $2.73, off its recent high of $4.25 reached in mid May.

The phase III "SUCCEED" study is designed to detect a 33% improvement in median progression-free survival between "rida" and placebo in patients with soft-tissue or bone sarcoma who were previously treated, successfully, with chemotherapy. Full enrollment in the study of 650 patients was reached in December 2009 and independent study monitors completed their last interim check in May, recommending the study proceed to a final analysis.

Ariad licensed worldwide commercial rights to rida to Merck ( MRK). The two companies recently restructured the terms of the partnership.

If you liked this article you might like

After Soaring to $150, Can Incyte Stir Up More Upside?

Biotech Buoyed by Deal Talk

The Next Target in Biotech Land

The Next Target in Biotech Land

Earnings Key to Next Week's Winners: Cramer's 'Mad Money' Recap (Friday 1/13/17)